Document is current
Any future updates will be listed below
-
Authors
Seçinti, Ekin https://orcid.org/0000-0001-7794-8500
Barrett, Louise
Delbecque, Laure
Hoyt, Margaret
Rosenberg-Yunger, Zahava
Baldasaro, Jessica
Schmidt, Kailynn
Mills, Jessica
Cano, Stefan
Gandhy, Chetan
Curtis, Sarah E.
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 13 November 2025
Accepted: 15 January 2026
First Online: 2 February 2026
Declarations
:
: Ekin Seçinti, Laure Delbecque, Margaret Hoyt, and Sarah E. Curtis are current employees and shareholders of Eli Lilly and Company; Chetan Gandhy was an employee of Eli Lilly and Company at the time of the study. Louise Barrett, Jessica Baldasaro, Kailynn Schmidt, Jessica Mills, and Stefan Cano are employees of Modus Outcomes who received financial support from Eli Lilly and Company to complete the literature review and patient interviews; Zahava Rosenberg-Yunger was an employee of Modus Outcomes at the time of the study.
: The study, including the protocol and the qualitative semi-structured interview guide, was approved by WCG (Cary, NC, USA), a fully accredited, independent, centralized institutional review board, on February 27, 2024. The study was conducted in accordance with both the Declaration of Helsinki and Good Clinical Practice guidelines. All eligible participants provided informed consent to participate in this study and be audio-recorded. Interview participants were aware that their responses may be collated and published.
